Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam

Future Microbiol. 2017 Nov:12:1323-1326. doi: 10.2217/fmb-2017-0018. Epub 2017 Oct 5.

Abstract

Ceftolozane/tazobactam is a novel fifth-generation cephalosporin β-lactamase combination with activity against extended-spectrum β-lactamases-producing enterobacteriaceae, and multidrug resistant Pseudomonas aeruginosa. However, clinical experience in real cases caused by these microorganisms is scarce. In this study, we describe three patients with severe infections caused by multidrug resistant and extensively drug-resistant (XDR) P. aeruginosa that were successfully treated with ceftolozane/tazobactam.

Keywords: Pseudomonas aeruginosa; ceftolozane/tazobactam; clinical experience; multidrug-resistant organisms; severe infections.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use*
  • Cephalosporins / therapeutic use*
  • Drug Resistance, Multiple, Bacterial*
  • Drug Synergism
  • Female
  • Humans
  • Male
  • Penicillanic Acid / analogs & derivatives*
  • Penicillanic Acid / therapeutic use
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas aeruginosa / drug effects*
  • Tazobactam
  • Treatment Outcome
  • beta-Lactamase Inhibitors / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • beta-Lactamase Inhibitors
  • ceftolozane, tazobactam drug combination
  • Penicillanic Acid
  • Tazobactam